Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis

被引：12
|
作者：
Nakamura, Akinobu [1 ]
Yoneda, Masato [2 ]
Fujita, Koji [2 ]
Tajima, Kazuki [1 ]
Kikuchi, Kaori [1 ]
Nakajima, Atsushi [2 ]
Maeda, Shin [2 ]
Terauchi, Yasuo [1 ]
机构：
[1] Yokohama City Univ, Grad Sch Med, Dept Endocrinol & Metab, Yokohama, Kanagawa 232, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol, Yokohama, Kanagawa 232, Japan
来源：
JOURNAL OF DIABETES INVESTIGATION | 2011年 / 2卷 / 06期
关键词：
Hyperglycemia; Hyperinsulinemia; Non-alcoholic steatohepatitis; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; HEPATOCELLULAR-CARCINOMA; DIABETES-MELLITUS; RISK; PATHOGENESIS; ASSOCIATION; PREVALENCE; FIBROSIS; CANCER;
D O I：
10.1111/j.2040-1124.2011.00134.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aims/Introduction: We investigated the relationship between non-alcoholic steatohepatitis (NASH) and different stages of fasting plasma glucose (FPG) concentrations, and the association between factors related to glucose tolerance and severity of NASH.
引用
收藏
页码：483 / 489
页数：7
相关论文
共 50 条
  • [21] Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
    Zhu, Bo
    Chan, Siu-Lung
    Li, Jack
    Li, Kathryn
    Wu, Hao
    Cui, Kui
    Chen, Hong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [22] Non-alcoholic steatohepatitis
    Romero-Gomez, Manuel
    MEDICINA CLINICA, 2022, 159 (08): : 388 - 395
  • [23] Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
    Dufour, Jean-Francois
    Caussy, Cyrielle
    Loomba, Rohit
    GUT, 2020, 69 (10) : 1877 - 1884
  • [24] Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis
    Gurka, Matthew J.
    Mack, Jasmine A.
    Chi, Xiaofei
    DeBoer, Mark D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (01) : 249 - 256
  • [25] Src kinase as a potential therapeutic target in non-alcoholic and alcoholic steatohepatitis
    Kurniawan, Dhadhang Wahyu
    Booijink, Richell
    Jajoriya, Arun Kumar
    Dhawan, Garima
    Mishra, Divya
    Oosterhuis, Dorenda
    Argemi, Josepmaria
    Storm, Gert
    Olinga, Peter
    Bataller, Ramon
    Mohanty, Sujit Kumar
    Mishra, Durga Prasad
    Prakash, Jai
    Bansal, Ruchi
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2022, 2 (01):
  • [26] Non-alcoholic Steatohepatitis (NASH) and alcoholic Steatohepatitis (ASH)
    Roeb, Elke
    DRUG RESEARCH, 2021, 71 : S16 - S18
  • [27] The therapeutic landscape of non-alcoholic steatohepatitis
    Perazzo, Hugo
    Dufour, Jean-Francois
    LIVER INTERNATIONAL, 2017, 37 (05) : 634 - 647
  • [28] Emerging drugs for non-alcoholic steatohepatitis
    Tomeno, Wataru
    Yoneda, Masato
    Imajo, Kento
    Ogawa, Yuji
    Kessoku, Takaomi
    Saito, Satoru
    Eguchi, Yuichiro
    Nakajima, Atsushi
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (03) : 279 - 290
  • [29] Future pharmacotherapy for non-alcoholic steatohepatitis
    De, Arka
    Duseja, Ajay
    NATIONAL MEDICAL JOURNAL OF INDIA, 2021, 34 (04): : 225 - 227
  • [30] Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
    Koo, Bo Kyung
    Kim, Donghee
    Joo, Sae Kyung
    Kim, Jung Ho
    Chang, Mee Soo
    Kim, Byeong Gwan
    Lee, Kook Lae
    Kim, Won
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : 123 - 131
12345